| Literature DB >> 28991267 |
Ophélie Rouxel1,2,3, Jennifer Da Silva1,2,3, Lucie Beaudoin1,2,3, Isabelle Nel1,2,3, Céline Tard1,2,3, Lucie Cagninacci1,2,3, Badr Kiaf1,2,3, Masaya Oshima1,2, Marc Diedisheim1,2, Marion Salou4, Alexandra Corbett5, Jamie Rossjohn6,7,8, James McCluskey5, Raphael Scharfmann1,2, Manuela Battaglia9, Michel Polak1,2,10,11, Olivier Lantz4, Jacques Beltrand1,2,10,11, Agnès Lehuen1,2,3.
Abstract
Type 1 diabetes (T1D) is an autoimmune disease that results from the destruction of pancreatic β-cells by the immune system that involves innate and adaptive immune cells. Mucosal-associated invariant T cells (MAIT cells) are innate-like T-cells that recognize derivatives of precursors of bacterial riboflavin presented by the major histocompatibility complex (MHC) class I-related molecule MR1. Since T1D is associated with modification of the gut microbiota, we investigated MAIT cells in this pathology. In patients with T1D and mice of the non-obese diabetic (NOD) strain, we detected alterations in MAIT cells, including increased production of granzyme B, which occurred before the onset of diabetes. Analysis of NOD mice that were deficient in MR1, and therefore lacked MAIT cells, revealed a loss of gut integrity and increased anti-islet responses associated with exacerbated diabetes. Together our data highlight the role of MAIT cells in the maintenance of gut integrity and the control of anti-islet autoimmune responses. Monitoring of MAIT cells might represent a new biomarker of T1D, while manipulation of these cells might open new therapeutic strategies.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28991267 PMCID: PMC6025738 DOI: 10.1038/ni.3854
Source DB: PubMed Journal: Nat Immunol ISSN: 1529-2908 Impact factor: 25.606